<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200509047350N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-14</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of olive leaf extract and curcumin combination on improvement of clinical signs and symptoms and quality of life in patients with external anogenital wart</public_title>
      <acronym></acronym>
      <scientific_title>The effect of olive leaf extract and curcumin combination on improvement of clinical signs and symptoms and quality of life in patients with external anogenital wart</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47991</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Routine treatment in both groups means that on the first day of treatment, the midwife will first cover the wart with Vaseline cream containing vitamin E and then place a full swab soaked in pedophyllin 20% on the wart. The solution should be on the lesion for 4 hours and not washed under any circumstances. Before applying the ointment, a thin layer of the drug is placed on the inside of the forearm for 20 minutes and the redness, itching, burning, swelling and skin lesions will be examined. The lesion will be washed with water. Then the site of the lesion is dried and patients, according to the control groups and olive-curcumin leaf extract, apply 10% ointment to the lesions with a swab, and do not wash it until the next dose. This is done from the first day of treatment after pedophilia (once a week) for 3 times a day until complete recovery (maximum 12 weeks). The exact time and date of the start of treatment will be recorded by the researcher and the patient will be given the necessary training to take the medication. To receive pedophylline, the patient sees a specialist once a week, and the disease is examined and, if necessary, continued treatment. How to blind the study is done in such a way that the patient and the researcher and statistical analyst do not know how to divide people into groups. Each person will receive their own code and will be grouped into 1.2 groups using coding. Then, with the help of an obstetrician's examination, the treatment process is checked by observing privacy and the principle of confidentiality. The patient informs the researcher of the time of recovery of the lesions after the start of treatment as the exact time and date. The number of lesions before consumption, daily (at intervals of weekly visits by the patient), is examined and recorded every week by a midwife by direct observation according to the time of complete recovery after taking the medication. The quality of life questionnaire will be completed by the researcher before starting treatment and after complete recovery. The researcher will follow the patient from the first day of treatment until the next visit (once a week) using a mobile phone and contacting the patient (self-report), in terms of side effects (pain, bleeding, scaling, itching). It should be noted that the follow-up of drug use and washing by the subjects will be done by telephone by the researcher. Patients who may have a full recovery earlier than the due date should report the exact date and time of the recovery to the researcher during these calls, Randomization description: Random block block The volume of each block is 4, so that 6 different combinations of 4 blocks are created and are selected randomly by placing the blocks, Blinding description: In this study, the Research Center codes the drug and placebo with specific and confidential codes. While using the patient, the researcher, the analyst, is not aware of the research groups (whether the patient has received the medication or the placebo) and is only in the groups with the medication codes they received. Finally, after analyzing the data, decryption is performed by the research center.</study_design>
      <phase>3</phase>
      <hc_freetext>Genital Warts.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Routine treatment with pedophile 20% once a week until clinical repair (maximum 12 weeks) and the use of 10% olive leaf extract ointment and 10% curcumin in the amount of 2 mm) (9 made by the University Health and Nutrition Research Center) Khorramabad Medical Sciences) 3 times a day until recovery (maximum 12 weeks).  On the first day of treatment, the midwife will first cover the wart with a vitamin E-containing Vaseline cream and then place a full 20% pedophile -soaked swab on the wart. The solution should be on the lesion for 4 hours and not washed under any circumstances. Before applying the ointment, a thin layer of the drug is placed on the inside of the forearm for 20 minutes and the redness, itching, burning, swelling and skin lesions will be examined. The lesion will be washed with water. Then the site of the lesion is dried and the patients extract 10% of the ointment from the olive-curcumin leaf extract with a swab, and do not wash it until the next dose. Intervention 2: Control group: Routine treatment with pedophyllin 20% once a week until clinical repair (maximum 12 weeks) and the use of placebo (size 2 mm) (manufactured by Khorramabad University of Medical Sciences) 3 times a day until Recovery (maximum 12 weeks). On the first day of treatment, the midwife will first cover the wart with a vitamin E-containing Vaseline cream and then place a full 20% pedophyllin -soaked swab on the wart. The solution should be on the lesion for 4 hours and not washed under any circumstances. Before applying the ointment, a thin layer of placebo is placed on the inside of the forearm for 20 minutes to examine for redness, itching, burning, swelling, and skin lesions. The lesion will be washed with water. Then the site of the lesion is dried and the patients are given a placebo with a swab to the lesion, to avoid washing it until the next dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the effect of the drug on primary and secondary outcomes.

When:
Start the access period 6 months after printing the results

To whom:
researchers

Conditions:
Researchers first obtain permission from the researcher and refer to their research objectives to use any data or information.

Where to obtain:
Postal address: Khorramabad, Lorestan University of Medical Sciences, Faculty of Nursing and Midwifery - Fatemeh Mehrabi Rad
Contact Number: 00986633120140
Email: fatememehrabirad@gmail.com

How to obtain:
Dear researchers, you can ask your questions via email address
Email: fatememehrabirad@gmail.com. We will answer your questions as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tahereh Toulabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Medical Sciences, Shahid Anoushirvan Rezaei Square, Moallem Street</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3330 0661</telephone>
        <email>toulabi_t@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Toulabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Medical Sciences , Shahid Anoushirvan Rezaei Square , Moallem Street</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3330 0661</telephone>
        <email>toulabi_t@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Confirmation and introduction of a midwifery specialist for the patient to enter the study (having external anogenital warts)
Age 18 and up
No pregnancy or lactation
The desire to participate in research and sign a conscious consent
Lack of incurable, metabolic and chronic diseases and weakness in the immune system
Do not use corticosteroids or antiviral drugs and weaken the immune system during research
Lack of pelvic inflammatory disease, other genital infectious diseases
Failure to participate in other research that in any way affects the results of the research
Phone access</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Lack of proper and appropriate use of drugs
Lack of desire to continue research
Any allergies caused by the drug
Disabling the patient or changing the patient's contact number and not answering the phone call
Pregnancy
Severe type of disease that requires surgery or systemic medication</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>A63.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anogenital (venereal) warts</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Routine treatment with pedophile 20% once a week until clinical repair (maximum 12 weeks) and the use of 10% olive leaf extract ointment and 10% curcumin in the amount of 2 mm) (9 made by the University Health and Nutrition Research Center) Khorramabad Medical Sciences) 3 times a day until recovery (maximum 12 weeks).  On the first day of treatment, the midwife will first cover the wart with a vitamin E-containing Vaseline cream and then place a full 20% pedophile -soaked swab on the wart. The solution should be on the lesion for 4 hours and not washed under any circumstances. Before applying the ointment, a thin layer of the drug is placed on the inside of the forearm for 20 minutes and the redness, itching, burning, swelling and skin lesions will be examined. The lesion will be washed with water. Then the site of the lesion is dried and the patients extract 10% of the ointment from the olive-curcumin leaf extract with a swab, and do not wash it until the next dose.</i_keyword>
      <i_keyword>Control group: Routine treatment with pedophyllin 20% once a week until clinical repair (maximum 12 weeks) and the use of placebo (size 2 mm) (manufactured by Khorramabad University of Medical Sciences) 3 times a day until Recovery (maximum 12 weeks). On the first day of treatment, the midwife will first cover the wart with a vitamin E-containing Vaseline cream and then place a full 20% pedophyllin -soaked swab on the wart. The solution should be on the lesion for 4 hours and not washed under any circumstances. Before applying the ointment, a thin layer of placebo is placed on the inside of the forearm for 20 minutes to examine for redness, itching, burning, swelling, and skin lesions. The lesion will be washed with water. Then the site of the lesion is dried and the patients are given a placebo with a swab to the lesion, to avoid washing it until the next dose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical Signs and Symptoms: In this study, the clinical signs and symptoms of itching, burning, pain, warts and bleeding are considered. Timepoint: Every week and the intervals between visits for a maximum of 12 weeks. Method of measurement: clinical examination, self-report.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of Life. Timepoint: The day before treatment, after clinical repair. Method of measurement: Life Quality Questionnaire 36 questions  SF36.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-06</approval_date>
        <contact_name>Ethics committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Lorestan University of Medical Sciences, Shahid Anoushirvan Rezaei Square, Moallem St. Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
